Scancell Holdings PLC (LON:SCLP)

Scancell Holdings PLC (LON:SCLP)

Share Price
9.05 p
0.55 (6.47 %)
Market Cap
£42.11 m
Proactive Investors - Run By Investors For Investors

Scancell Holdings PLC

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

Market: LSE:SCLP
52-week High/Low: 13.90p / 3.00p
Sector: Pharma & Biotech
Market Cap: £42.11 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Scancell Holdings PLC

Scancell Holdings PLC Timeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use